华昊中天医药H股全流通获备案，核心产品上市在即

Group 1: Core Insights - The company has made significant progress in capital operations, product development, and legal affairs [1] - The stock has shown notable events worth attention as of February 13, 2026 [2] Group 2: Recent Events - On February 5, 2026, the company received a notification from the China Securities Regulatory Commission regarding the H-share full circulation filing, valid for 12 months, which may affect the liquidity and shareholder structure of the company's shares [3] Group 3: Business Progress - The company's first innovative drug, injectable imatinib, is expected to be approved for domestic listing in 2026. Additionally, three drugs (XNW5004, XNW27011, and XNW28012) have received breakthrough therapy designation from the CDE and are anticipated to be launched between 2027 and 2028, making product pipeline progress a core variable affecting revenue inflection points [4] Group 4: Financial Performance - The company has achieved a cumulative agreement transaction amount exceeding $2 billion through external licensing collaborations, with $130 million (pre-tax) received as an irrevocable upfront payment in 2025, and is expected to achieve profitability at the company level (after deducting non-recurring items) for that year. The subsequent collection of business development funds is worth monitoring [5] Group 5: Company Status - Regarding the investment recovery issue of the LFM Stable Income Fund SP fund subscribed by the company's wholly-owned subsidiary US-Biostar, the Cayman Islands court approved the appointment of a receiver for the fund's management and liquidation process on December 3, 2025. The progress of fund recovery may impact the company's cash flow [6] Group 6: Project Advancement - The company has submitted listing application materials to the Shanghai Stock Exchange's Sci-Tech Innovation Board, aiming to raise 1.5 billion yuan for innovative drug research and industrialization projects. The subsequent review results will significantly impact the company's capital path [7]